5 YEARS IN THE MAKING, TARGETED NATIONAL LUNG CANCER SCREENING PROGRAM COMMENCES IN 2025 Lung Foundation Australia CEO talks about opportunity to treat patients presenting at early stage instead of late stage
Australian Health Journal SEGMENT
Filmed in Adelaide | February 2025
INTERVIEWED
Mark Brooke, Chief Executive Officer
Lung Foundation Australia
In February 2025, Australian Health Journal spoke with Mark Brooke, Chief Executive Officer of Lung Foundation Australia, at the 10th Australian Lung Cancer Conference in Adelaide, on the upcoming commencement of the National Lung Cancer Screening Program (NLCSP)
The conference theme, Evolution and Revolution in Lung Cancer, was chosen in recognition of the historic significance of 2025. Mr Brooke emphasised the importance of the National Lung Cancer Screening Program, which is set to begin on July 1st.
The Australian Government’s $267 million investment in the National Lung Cancer Screening Program aims to vastly improve lung cancer detection, treatment, and survivorship. When launched it will be Australia’s first new screening program in over 20 years.
Following a request from the Australian Government, Cancer Australia undertook an enquiry into lung cancer screening, publishing a report that informed the development of the NLCSP.
As the health peak advisory body to the Department of Health and Aged Care, the Lung Foundation aims to amplify the lived experiences of patients within this program. After nearly five years of preparation, the initiative is a crucial step in moving lung cancer diagnoses from late stages (three and four) to early stages (one and two), significantly improving patient care.
Mr Brooke expressed optimism that the timing for this screening program is ideal for Australia, given that lung cancer is the nation’s leading cancer killer. The program’s implementation is particularly challenging because it integrates with General Practice, requiring collaboration from healthcare professionals. While acknowledging potential hurdles, Mr Brooke is confident that the organisation and preparation for the program are well on track.
The program specifically addresses the needs of priority populations, including Aboriginal and Torres Strait Islander communities, who are disproportionately affected by lung cancer. Efforts have been made to provide culturally safe experiences and mobile CT services through partnerships with organisations like Heart of Australia, ensuring access for rural and remote populations.
Over the past five years, the Lung Foundation has collaborated with state governments to support the role of specialist lung cancer nurses. This initiative has proven to enhance timely care and improve patient pathways, ultimately striving for better outcomes in lung cancer treatment.
-
Ensuring stringent quality standards in the lifecycle of medical devices
Dr Jasjit Baveja is the Associate Director of Policy at the Medical Technology Association of Australia (MTAA), where she oversees regulatory affairs, clinical code of practice, procurement, industry policy, reimbursement, and advocacy. With over 20 years of experience in the medical device regulatory space, Dr Bavej’s expertise lies in providing educational opportunities for regulatory professionals in Australia to ensure continuous learning and professional development. She collaborates closely with the Therapeutic Goods Administration (TGA) to run workshops that provide invaluable experience, networking opportunities, and skill enhancement.
-
The role of genomic screening in transforming public health
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.
-
Cardinal Health brings device reprocessing plant to Australia
Cardinal Health is global medical products manufacturer and leading provider of single-use device reprocessing services in the U.S. In Australia and New Zealand, as one of the largest suppliers of medical devices, announced on 23 May 2024 that it will be opening a single-use medical device reprocessing facility in Australia – its first reprocessing facility outside the United States.
On 18 March 2025 at the Health Innovation Living Lab at the John Hunter Hospital, a further announcement was made, on the chosen single-use medical device remanufacturing facility in Beresfield, Newcastle, set to commence operation late 2025, supported by the NSW Department of Primary Industries and Regional Development.
